Company: USPH
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001140361-25-013467
Chunk: 51

Company: U S PHYSICAL THERAPY INC /NV
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 51
---
    $2,446,657 |     |      $1,056,375 |     |         $829,949 |     |                         100 |     | 100 |     | $52,491,000 |     | $38,435,000 |     | $70,017,000 |

| 1) | The PEO isChristopher J. Readingfor each of the years presented. The non-PEO NEOs for are Carey P. Hendrickson, Eric J. Williams, Graham D. Reeve, and Richard Binstein for the years 2024, 2023 and 2022, Carey P. Hendrickson, Eric J. Williams, Glenn D. McDowell, and Graham D. Reeve for 2021 and Carey P. Hendrickson, Lawrance W. MacAfee, Glenn D. McDowell, and Graham D. Reeve for 2020. |

| 2) | Net income includes earnings attributable to non-controlling interests. |

| 3) | Operating Results, a non-GAAP measure, equals net income attributable to Company stockholders less, changes in revaluation of a put-right liability, any relief funds, clinic closure costs, changes in fair value of contingent earn-out consideration, business acquisition related costs, non-cash impairment charges and any allocations to non-controlling interests, all net of taxes. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact. |

| 4) | On August 14, 2012, our common stock began trading on the NYSE. The Total Shareholder Return assumes that $100 was invested in our common stock and the common stock on each of the companies listed on The NYSE Healthcare Index (the Company’s Peer Group), on December 31, 2020 and that any dividends were reinvested. |

| 5) | For a computation of compensation actually paid to the PEO and average compensation actually paid to non-PEO NEOs, please refer to the subsequent table. |

| 6) | Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to the Company stockholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, payments received from the federal government under the Corona virus Aid, Relief and Economic Security Act, changes in revaluation of put-right liability, equity-based awards compensation expense